¹ú¼ÊÓÐÊý²¡ÈÕØ¹Ø×¢Ó¤¶ù¾·ÂÎÖ¢£¬£¬£¬£¬£¬£¬ÈÃÓÐÊý±»Íû¼û
¹ú¼ÊÓÐÊý²¡ÈÕ
¡°´ÉÍÞÍÞ¡±¡¢¡°½¥¶³ÈË¡±¡¢¡°ÔÂÁÁº¢×Ó¡±¡¢¡°µç±¦±¦¡±¡¡ÕâЩ¿É°®µÄÃû×Ö±³ºó£¬£¬£¬£¬£¬£¬×Åʵ¶ÔÓ¦µÄÊÇÒ»¸ö¸öÓÐÊý²¡¡£¡£¡£¡£¡£¡£¡£¡°µç±¦±¦¡±¼´ÊǶԡ°Ó¤¶ù¾·ÂÎÖ¢¡±»¼¶ùµÄ³Æºô£¬£¬£¬£¬£¬£¬ÓÉÓÚº¢×Ó·¢²¡Ê±¡°ò¥Êס±¡¢¡°Óµ±§¡±µÄÖ¢×´Ïñ´¥µçÒ»Ñù¶øµÃÃû¡£¡£¡£¡£¡£¡£¡£
½ñÌìÊÇ2ÔÂ28ÈÕ£¬£¬£¬£¬£¬£¬Ò²Êǹú¼ÊÓÐÊý²¡ÈÕ¡£¡£¡£¡£¡£¡£¡£½ñÄê¹ú¼ÊÓÐÊý²¡ÈÕµÄÖ÷ÌâÊÇ¡°Share Your Colours¡±£¨·ÖÏíÄãµÄÉúÃüÉ«²Ê£©¡£¡£¡£¡£¡£¡£¡£
ÓÐÊý²¡²¢²»ÓÐÊý£¬£¬£¬£¬£¬£¬ÔçÕïÔçÖÎÊÇÒªº¦
?¡°Ò©¡±ÓÐËùÒÀ£¬£¬£¬£¬£¬£¬ÕÕÁÁ¡°Éú¶øÓÐÊý¡±µÄËûÃÇ
³ýÁËÄÑÒÔÈ·Õ£¬£¬£¬£¬£¬ÖÎÁÆÒ©ÎïµÄȱ·¦ÊÇÓÐÊý²¡»¼ÕßÖÎÁÆÂ·ÉÏÒ»´óÄÑÌâ¡£¡£¡£¡£¡£¡£¡£È«Çò7000¶àÖÖÓÐÊý²¡£¬£¬£¬£¬£¬£¬ÓÐÒ©¿ÉÖεıÈÀýȱ·¦10%¡£¡£¡£¡£¡£¡£¡£ºÜÐÒÔË£¬£¬£¬£¬£¬£¬ISÊÇÆäÖÐÖ®Ò»¡£¡£¡£¡£¡£¡£¡£
°±¼ºÏ©Ëá×÷ΪISÒ»ÏßÖÎÁÆÒ©Î£¬£¬£¬£¬£¬TSC°éISÊ×ѡҩÎ£¬£¬£¬£¬£¬ÒѾÔÚÅ·ÖÞ¹ú¼ÒÉÏÊÐ30ÓàÄê4¡£¡£¡£¡£¡£¡£¡£Î¬¸ñ¶¨?(°±¼ºÏ©Ëá¿Ú·þÈÜÒºÓÃÉ¢)ÓÚ2022ÄêÔÚÖйúÕýʽÉÏÊУ¬£¬£¬£¬£¬£¬ÊǺ£ÄÚÊ׸öÕýʽÉÏÊеݱ¼ºÏ©Ëá¡£¡£¡£¡£¡£¡£¡£ÆäδÔÚº£ÄÚÉÏÊÐ֮ǰ£¬£¬£¬£¬£¬£¬º£ÄÚ¹ØÓÚÕâÒ»¼²²¡µÄÖÎÁÆ´¦ÔÚÉÙÒ©»òÎÞÒ©¿ÉÓõĽ׶Σ¬£¬£¬£¬£¬£¬»¼¶ùÓÃÒ©ÐèҪרÃÅ´ÓÍâÑó´ú¹º£¬£¬£¬£¬£¬£¬²¢ÇÒÓÐЩҩÎïÓÉÓÚÇå¾²ÎÊÌ⣬£¬£¬£¬£¬£¬±£´æÓÃÒ©Òþ»¼£¬£¬£¬£¬£¬£¬ÔçǰÓÉÓÚÒßÇéÔµ¹ÊÔÓÉ£¬£¬£¬£¬£¬£¬¸üÊÇʱ³£ÃæÁÙ¶ÏÒ©µÄΣº¦¡£¡£¡£¡£¡£¡£¡£
°±¼ºÏ©ËáµÄ×÷ÓûúÖÆÖ÷ÒªÊÇͨ¹ý²»¿ÉÄæµØÒÖÖÆGABAת°±Ã¸À´ÒÖÖÆGABAµÄÆÊÎö´úл£¬£¬£¬£¬£¬£¬´Ó¶øÌá¸ß¾þÄÔÖÐGABAµÄŨ¶È¡£¡£¡£¡£¡£¡£¡£¸ÃÒ©¿ÉÒÔʵʱ¡¢ÓÐÓÿØÖÆ»¼¶ùñ²ðï¾·ÂΣ¬£¬£¬£¬£¬£¬ÏÔןÄÉÆÔ¤ºó£¬£¬£¬£¬£¬£¬Ìá¸ßIS»¼¶ùÉúÑÄÂʼ°ÉúÑÄÖÊÁ¿5-6¡£¡£¡£¡£¡£¡£¡£
2021Äê12Ô£¬£¬£¬£¬£¬£¬ÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©ÓëÖйú¿¹ñ²ðïÐ»á¸æ¿¢Õ½ÂÔÏàÖú£¬£¬£¬£¬£¬£¬ÅäºÏ½¨Éè½á½ÚÐÔÓ²»¯¼°ñ²ðïÓÐÊý²¡×¨²¡Î¯Ô±»á£¬£¬£¬£¬£¬£¬Íƶ¯º£ÄÚñ²ðïÓÐÊý²¡ÕïÁÆË®Æ½µÄÌáÉý£¬£¬£¬£¬£¬£¬Èøü¶àµÄ»¼¶ùÄܽÓÊÜÔçÕï¡¢ÔçÖΡ£¡£¡£¡£¡£¡£¡£ÎªÇÐʵÓÐÓõØ×ÊÖú»¼¶ù¼ÒÍ¥¼õÇáÓÃÒ©¾¼Ã¼ç¸º£¬£¬£¬£¬£¬£¬ÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©Æô¶¯»¼Õ߹ذ®¸£ÀûÍýÏ룬£¬£¬£¬£¬£¬Ð¯ÊÖÐÐҵר¼Ò´Ó¼²²¡ÕïÖΡ¢»¼ÕßÔ®Öú¡¢ÓÃÒ©°ü¹Ü¡¢¼ÒÍ¥¹Ø°®µÈ·½Ãæ½â¾ö²¿·ÖÓÐÊý²¡»¼Õß¼°Æä¼ÒÍ¥ÄÑÌâ¡£¡£¡£¡£¡£¡£¡£2022Ä꣬£¬£¬£¬£¬£¬ÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©³ÉÔ±ÆóÒµÍò°îÒ½Ò©¾ÙÐÐÎåÊ®Óೡ»¼Õß¿ÆÆÕ¹«Òæ½²×ù£¬£¬£¬£¬£¬£¬»¼Õ߹ذ®¸£ÀûÍýÏë¹²»Ý¼°1300Ãû»¼¶ù£¬£¬£¬£¬£¬£¬¼«´óµÄ¼õÇáÁË»¼Õß¾¼Ã¼ç¸º£¬£¬£¬£¬£¬£¬ÌáÉýÒ©Îï¿É¼°ÐÔÓëÒÀ´ÓÐÔ¡£¡£¡£¡£¡£¡£¡£
³ýÁËIS£¬£¬£¬£¬£¬£¬ÉÐÓÐÒ»ÖÖÓÐÊýµÄ¼²²¡¶à·¢ÓÚ¶ùͯ¡ª¡ªÂýÐÔÈâÑ¿Ö×(chronic granulomatous disease,CGD)£¬£¬£¬£¬£¬£¬ÊÇÖÂËÀÐÔÒÅ´«ÐÔ°×ϸ°û¹¦Ð§È±ÏÝ£¬£¬£¬£¬£¬£¬¶àΪÐÔÁªÒþÐÔÒÅ´«¡£¡£¡£¡£¡£¡£¡£Ñ¬È¾ÊÇCGD»¼¶ù×î³£¼ûµÄÁÙ´²ÌåÏÖ£¬£¬£¬£¬£¬£¬Ö÷Òª²¢·¢Ö¢¼ûÓÚÖÖÖÖÔàÆ÷»¯Å§ÐÔѬȾ£¬£¬£¬£¬£¬£¬È縹ǻŧÖס¢¸ÎŧÖס¢ÄÔĤÑס¢ÑÏÖØÕß±¬·¢°ÜѪ֢¶øÎ£¼°ÉúÃü¡£¡£¡£¡£¡£¡£¡£¶øÙ¤Âí×ÌÈÅËØ£¨IFN¦Ã£©µÄÓ¦ÓÃÄÜÓÐÓÿØÖÆCGD»¼ÕßµÄѬȾ²¢¸ÄÉÆÉúÑÄÇéÐΣ¬£¬£¬£¬£¬£¬Îª»¼¶ùµÄ¼²²¡ÖÎÀí´øÀ´Ã÷È·µÄ»ñÒæ7¡¢8¡£¡£¡£¡£¡£¡£¡£ÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©³ÉÔ±ÆóÒµ×ÔÖ÷Ñз¢ÇÒÉú²úµÄIFN¦Ã£¬£¬£¬£¬£¬£¬Îªº£ÄÚΨһIFN¦Ã£¬£¬£¬£¬£¬£¬×ÝȻÿһ´ÎÆô¶¯Ò©ÎïÉú²úµÄ±¾Ç®´óÓÚÊÕÈ룬£¬£¬£¬£¬£¬³Ð¼Ì¡°¹Ø°®ÉúÃü¡±µÄ¼ÛÖµ¹Û£¬£¬£¬£¬£¬£¬ÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©ÈÔÒ»Á¬Éú²ú£¬£¬£¬£¬£¬£¬ÖÂÁ¦Îª»¼¶ù¼ÒÍ¥´øÀ´ºã¾ÃÎÞ²¡ÉúÑĵÄÏ£Íû¡£¡£¡£¡£¡£¡£¡£
²»Òò¼²²¡ÓÐÊý¶øÖÃÈôØèÎÅ£¬£¬£¬£¬£¬£¬²»ÒòȱҽÉÙÒ©¶øÖÃÖ®²»²Ç£¬£¬£¬£¬£¬£¬ÓÐÊý²¡ÈºÌåÐèÒªÉç»á¸÷·½¹Ø×¢¡£¡£¡£¡£¡£¡£¡£ÌìÆø½¥Å¯£¬£¬£¬£¬£¬£¬Ñô¹âÕýºÃ£¬£¬£¬£¬£¬£¬ÈÃÎÒÃÇÒ»ÆðÆð¾¢£¬£¬£¬£¬£¬£¬½«Ï£ÍûµÄ¹âÕÕ½øÃ¿Ò»¸öÓÐÊý²¡»¼ÕߵļÒÍ¥£¬£¬£¬£¬£¬£¬ÈÃÏ£Íû²»ÔÙÓÐÊý¡£¡£¡£¡£¡£¡£¡£
ÑÓÉìÔĶÁ£ºÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©ÓëÓÐÊý²¡
2019Äê9Ô£¬£¬£¬£¬£¬£¬ÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©¼ÓÈëÖйúÓÐÊý²¡Í¬ÃË¡£¡£¡£¡£¡£¡£¡£¸ÃͬÃËÓɱ±¾©ÐºÍÒ½Ôº¡¢ÖйúÒ½Ò©Á¢ÒìÔö½ø»á¡¢ÖйúҽԺлáµÈǣͷÌᳫ£¬£¬£¬£¬£¬£¬Ö¼ÔÚÍÆ¶¯Ò½Ñ§ÔÚÓÐÊý²¡Ñо¿·½ÃæÈ¡µÃÖØ´óÍ»ÆÆ£¬£¬£¬£¬£¬£¬ÌáÉýÓÐÊý²¡·ÀÖÎÓë°ü¹Üˮƽ£¬£¬£¬£¬£¬£¬Ôö½øÓÐÊý²¡ÁÙ´²¡¢¿ÆÑÐÓë¹Â¶ùÒ©¿ª·¢µÄÐͬÁ¢Òì¡£¡£¡£¡£¡£¡£¡£
2020Äê12ÔÂ23ÈÕ£¬£¬£¬£¬£¬£¬ÔÚÉϺ£ÊÐÓÅÉúÓÅÓý¿ÆÑ§Ð»á£¨ÉϺ£Êи¾Ó×±£½¡Ð»á£©¡¢ÉϺ£ÊÐÓÐÊý²¡·ÀÖλù½ð»á¡¢ÉϺ£¸ßˮƽµØ·½¸ßÐ£ÖØµãÁ¢ÒìÍŶӣ¨¶ùͯ¿µ½¡Î¬»¤ÓëÔö½ø£©ÏîĿר¼Ò×éµÄÖ¸µ¼Ï£¬£¬£¬£¬£¬£¬ÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©Ð¯ÊÖÉϺ£ÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾¹«Òæ»ù½ð»á¡¢¸´µ©´óѧÁ¥Êô¶ù¿ÆÒ½Ôº£¬£¬£¬£¬£¬£¬ÅäºÏÆô¶¯¡°ÐÇÑ¿¡±¶ùͯÓÐÊý²¡¹Ø°®×¨Ïî»ù½ð£¬£¬£¬£¬£¬£¬ÖÂÁ¦ÓÚΪ¸ü¶à¶ùͯÓÐÊý²¡»¼ÕßÌṩȫÉúÃüÖÜÆÚµÄÕչ˺͹ذ®¡£¡£¡£¡£¡£¡£¡£
2022Äê1Ô£¬£¬£¬£¬£¬£¬ÓÉÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©³ÉÔ±ÆóÒµÍò°îÒ½Ò©Òý½øµÄÖйúÊ׸öÈë¿Ú°±¼ºÏ©ËáÉ¢¼Á¡ª¡ªÎ¬¸ñ¶¨?ÉÏÊУ¬£¬£¬£¬£¬£¬Ö÷ÒªÓÃÓÚ1¸öÔµ½2ËêÓ¤¶ùµÄÓ¤¶ù¾·ÂÎÖ¢£¬£¬£¬£¬£¬£¬¸ÃÒ©¿ÉÒÔʵʱ¡¢ÓÐÓÿØÖÆ»¼¶ùñ²ðï¾·ÂΣ¬£¬£¬£¬£¬£¬ÏÔןÄÉÆÔ¤ºó£¬£¬£¬£¬£¬£¬Ìá¸ßIS»¼¶ùÉúÑÄÂʼ°ÉúÑÄÖÊÁ¿¡£¡£¡£¡£¡£¡£¡£
ÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©¼¯ÍÅÆð¾¢ÏìÓ¦¹ú¼Ò¶¦Á¦´ó¾ÙÌᳫÁÙ´²¼±ÐèºÍÓÐÊý²¡Ò©ÎïµÄ×¢²áÑз¢£¬£¬£¬£¬£¬£¬ÏÖÔÚͨ¹ýÔÊÐíÒý½øµÄģʽ£¬£¬£¬£¬£¬£¬ÔÚÓ¤¶ù¾·ÂÎÖ¢¡¢ÌØ·¢ÐÔ·ÎÏËά»¯¡¢·Î¶¯Âö¸ßѹµÈ˳Ӧ֢£¨²Î¿¼¹ú¼ÒÎÀÉú¿µ½¡Î¯Ô±»áÐû²¼µÄ¡¶µÚÒ»ÅúÓÐÊý²¡Ä¿Â¼¡·£©ÓµÓÐÓÐÊý²¡Ò©Î£¬£¬£¬£¬£¬ÖÂÁ¦ÓÚÌá¸ßÁ¢ÒìÖÎÁÆÒ©ÎïÔÚÓÐÊý²¡»¼ÕßÖеĿɼ°ÐÔ¡£¡£¡£¡£¡£¡£¡£
²Î¿¼ÎÄÏ×£º
1¡¢¹ù»¢, Ö£àþ. Ó¤¶ù¾·Âι²Ê¶½â¶Á[J]. ÊÊÓöù¿ÆÁÙ´²ÔÓÖ¾, 2011, 26(12):978-980.
2¡¢Curatolo P, et al. Eur J Paediatr Neurol.?2018 Sep;22(5) 738-748.
3¡¢Peron A, et al. Am J Med Genet C Semin Med Genet.?2018?Sep;178(3):281-290.
4¡¢Ben-Menachem E.Mechanism of action of vigabatrin: correcting misperceptions. Acta Neurol ScandSuppl. 2011(192): 5¨C15, doi: 10.1111/j.1600-0404.2011.01596.x, indexed inPubmed: 22061176.
5¡¢°±¼ºÏ©Ëá˵Ã÷Êé
6¡¢Jackson MC,Jafarpour S, Klehm J, et al. Effect of vigabatrin on seizure control and safetyprofile in different subgroups of children with epilepsy. Epilepsia. 2017;58(9): 1575¨C1585.
7¡¢Ð¡¶ùÖØ¸´ÑÏÖØÑ¬È¾£ºÌá·À¡°ÂýÐÔÈâÑ¿Öײ¡£¬£¬£¬£¬£¬£¬¡¶¹«¹²Ò½Ñ§¡·? 2017ÄêµÚ5ÆÚ24-24
8¡¢çÑÒ«·¼.С¶ùÂýÐÔÈâÑ¿Öײ¡:£® ¡¶ ÍâÑóҽѧ.ÁÙ´²·ÅÉäѧ·Ö²á ¡· £¬£¬£¬£¬£¬£¬ 1990





